Skip to main content


Pioneering chRDNA Guides

CRISPR genome editing uses easily designed, modular, biological tools to make DNA changes in living cells. There are two basic components of CRISPR systems: the nuclease protein(s) that cut DNA and the RNA molecule(s) that guide the nuclease to generate a site-specific, double-stranded break, leading to editing at the targeted genomic site. CRISPR systems occasionally edit unintended genomic sites, known as off-target editing, which may lead to harmful effects on cellular function.

In response to this challenge, Caribou has developed chRDNAs (pronounced “Chardonnays”), highly specific RNA-DNA hybrid guides that direct substantially more precise genome editing than all RNA guides. chRDNAs drive highly specific, multiplex genome editing including gene insertion. Caribou uses chRDNA guides in concert with CRISPR enzymes to develop complex immune cell therapies.

We are now using these chRDNAs to power the development of our CRISPR-edited therapies by guiding cellular editing with the highest level of fidelity.

CRISPR guides composed of RNA & DNA (chRDNAs) reduce off-target editing. All DNA guides fail to support editing activity. All RNA guides lead to both on-and off-target editing. chRDNAs contain a mixture of RNA and DNA and preferentially target the on-target site with high specificity.


Caribou is advancing multiple gene-edited, off-the-shelf cell therapies for cancer. Learn more.

CRISPR-Cas Publications

Explore the extensive library of research publications from the exciting fields of CRISPR-Cas biology and genome engineering. Learn more.

Contact Us

For media and investor inquiries and general information, click here.